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SECRETED TUMOR-ASSOCIATED
CYTOCHROME AS A BLOOD-BASED
BIOMARKER FOR CANCER

2007, 105:16-36). Recently, Pgrmcl was identified as a
sigma-2 receptor (S2R), with a clear role in tumor cell
survival.
Pgrmcl is also induced in multiple tumor types. For
example, Pgrmcl is induced in approximately approximately one-half of breast tumors compared to matched
nonmalignant tissue, and Pgrmcl is enriched in estrogen
receptor-negative breast tumors (Crudden et al., Tumour
Biol 2005, 26:142-6; Neubauer et al., Breast Cancer Res
2008, 10:R85). In ovarian cancer, Pgrmcl expression
increases with tumor stage, and Pgrmcl is also enriched in
colon and lung cancers (Peluso et al., J Clin Endocrinol
Metab 2008, 93:1592-9; Letwin et al., Cancer Res 2005
65:1814-21; Irby et al., Cancer Res 2005, 65:1814-21;
Difilippantonio et al., Eur J Cancer 2003; 39:1936-47). The
mechanism through which Pgrmcl is induced in tumors is
unclear, but may include induction by carcinogenic compounds (Difilippantonio 2003; Selmin et al., Carcinogenesis
1996; 17:2609-15; Nie et al., Mo! Carcinog 2006; 45:91433). Pgrmcl is inhibited by a small molecule ligand called
AG-205, which inhibits growth in tumor cells and decreases
EGFR levels (Ahmed et al., J Pharmacol Exp Ther 2010,
333:564-73; Ahmed et al., J Biol Chem 2010, 285:2477582). Pgrmcl also contributes to multiple features of tumor
growth. In lung adenocarcinoma cells, Pgrmcl promotes
proliferation, anchorage-independent growth, migration,
primary tumor growth and metastasis (Ahmed et al., J
Pharmacol Exp Ther 2010). Pgrmcl has a similar biological
role in ovarian cancer, where it regulates tumor growth as
well as angiogenesis and tumor pathology (Peluso et al.,
Endocrinology 2009, 150:4846-54). Pgrmcl also suppresses
apoptosis in immortalized granulosa and ovarian cancer
cells (Peluso et al., Endocrinology 2006, 147:3133-40;
Peluso et al., J Clin Endocrinol Metab 2008, 93: 1592-9) and
contributes to mitotic progression in ovarian cancer (Lodde
et al., Biol Reprod 2010, 84:215-222). Pgrmcl is inhibited
by a small molecule ligand called AG-205, which inhibits
growth in tumor cells and decreases EGFR levels (Yoshitani
et al., Proteomics 2005, 5:1472-80; Ahmed et al., J Pharmacol Exp Ther 2010; Ahmed et al., J Biol Chem 2010.

RELATED APPLICATIONS

5

This application claims priority under 35 U.S.C. 119(e) to
provisional application No. 61/701,449 filed Sep. 14, 2012,
the disclosure of which is incorporated herein in its entirety.
10

BACKGROUND OF THE INVENTION
The present invention relates generally methods for the
detection and diagnosis of cancer in a subject. More particularly, the invention relates to methods and kits for
detecting Pgrmcl (progesterone receptor membrane component 1) in a bodily fluid sample to facilitate the detection and
diagnosis of cancer, particularly lung cancer.
Cancer is one of the leading causes of death, and there is
an urgent need for new biomarkers and therapeutic targets
and method for early detection of cancer. Lung cancer is the
leading cause of cancer death worldwide, resulting in 150,
000 deaths per year in the United States. The mortality rate
from lung cancer is greater than the combined mortality
from breast, prostate and colorectal cancers. On the basis of
morphology, lung cancer can be broadly classified into four
main categories namely, adenocarcinoma, squamous cell
carcinoma, large cell undifferentiated carcinoma and small
cell carcinoma. Both squamous cell carcinoma and small
cell carcinoma are strongly associated with a smoking
history.
Adenocarcinoma, squamous cell carcinoma, and large cell
undifferentiated carcinoma are usually referred as "nonsmall cell carcinoma." They are relatively chemo-resistant,
and hence the mainstay of treatment is surgery. By contrast,
small cell carcinoma has a higher propensity for distant
metastases and is mainly treated by chemotherapy.
While biopsy can be used to diagnose various cancers, it
is an invasive procedure and, therefore, less than desirable.
Other diagnostic methods for cancers include ultrasound and
computed tomography (CT) scan. Nonetheless, methods and
kits for detecting biomarkers associated with cancer, particularly biomarkers present in a blood or serum sample, are
urgently needed to facilitate early detection and treatment of
cancer.
EGFR (epidermal growth factor receptor) is one of the
most promising therapeutic targets in lung cancer, and
EGFR inhibitors have produced positive clinical results,
particularly for patients with activating mutations in the
EGFR kinase domain (Gazdar A F., Oncogene 2009,28
Suppl 1:S24-31; Lynch et al., The New England Journal of
Medicine 2004; 350:2129-39; Pao et al., Proc Natl Acad Sci
USA 2004; 101: 13306-11 ).
Pgrmcl (progesterone receptor membrane component) is
a microsomal protein that colocalizes with EGFR in the
endoplasmic reticulum or punctate cytoplasmic sites.
Pgrmcl associates with EGFR in lung cancer cells and
increases susceptibility to the EGFR inhibitor erlotinib, it is
also a cytochrome b5 related protein. (Hughes et al., Cell
Metab 2007; 5:143-9; Ahmed et al., J Biol Chem 2010,
285:24775-82; Crudden, Chitti and Craven R J., J Pharmacol Exp Ther 2006, 316:448-55; Nolte et al., Biochim
Biophys Acta 2000; 1543:123-30; Peluso, Romak, and Liu,
Endocrinology 2008; 149:534-43; Min et al., FEBS J 2005,
272:5832-43; Mifsud and Bateman, Genome Biol 2002, 3:
RESEARCH0068; Cahill, J Steroid Biochem Mo! Biol
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The invention described herein relates to methods that
facilitate the diagnosis of cancer in a subject, determining
the stage of the cancer, and determining the prognosis for
and/or treatment of a subject having a cancer, e.g., a lung
cancer. Prior to this invention Pgrmcl was not known to be
a secreted protein and was not detected in bodily fluids, e.g.
blood, plasma or serum, or in subfractions of such fluids,
e.g., exosome-containing fractions. Thus, secreted Pgrmcl
is a biomarker for detecting the presence of cancer in a
subject and for monitoring cancer progression in a subject
by assaying its levels in a bodily fluid.
An aspect of this invention is a method for detecting
cancer in a subject by measuring the levels of Pgrmcl in a
bodily fluid, wherein the level of Pgrmcl in a bodily fluid
facilitates determining whether a subject has a cancer. Measuring the levels of Pgrmcl in a bodily fluid is also useful in
assessing the stage of the cancer, particularly stage 1 lung
cancer where the cancer limited to the lung and hasn't spread
to the lymph nodes and wherein the tumor is generally
smaller, e.g., less than about 2 inches (5 centimeters) across.
Also described herein are methods for monitoring the progression of a cancer in a subject.
Thus the methods of the invention can also be used to
assess cancer status, particularly lung cancer status, in a

US 10,288,626 B2
3

4

subject. "Cancer status" in the context of the present invention includes, inter alia, the presence or absence of disease,
the risk of developing disease, the stage of the disease, and
the effectiveness of treatment of disease. Based on this
status, further procedures may be indicated, including additional diagnostic tests or therapeutic procedures or regimens,
such as endoscopy, biopsy, surgery, chemotherapy, immunotherapy, and radiation therapy.
The invention also contemplates a kit for use in detecting
and diagnosing cancer in a subject, thereby assessing cancer
status in a subject. Kits within the invention comprise, for
example, and antibody that specifically binds to Pgrmcl,
e.g., a polyclonal or monoclonal antibody that binds to
native Pgrmcl, or denatured Pgrmc 1, preferably an antibody
that binds to a native Pgrmcl, and directions for detecting
Pgrmcl in a bodily fluid sample. The kit may also include a
control reference, indicating the levels of Pgrmcl in a
subject without cancer (a negative control reference) or
indicating the levels of Pgrmcl in a subject with a cancer (a
positive control reference). The positive control references
may indicate the levels of Pgrmcl in subjects having a
cancer, e.g., a lung cancer, a breast cancer, an ovarian cancer,
an oral cancer or a head or neck cancer.

panel, lane 1). (D) Adenoviruses driving the expression of a
control protein (Lacz, solid line) or a heme-binding-deficient mutant of Pgrmcl (Pgr-hbd, dashed line) demonstrated
that the inactive Pgrmcl protein inhibited H226 cell growth.
Cells were maintained in media lacking serum for the
indicated times. (E) The expression of the exogenous
Pgrmcl-hbd protein was detected by western blot in NCIH226 cells infected with a control adenovirus (lane 1),
encoding Lacz, or the Pgrmcl-hbd expression virus (lane 2).
The top panel was probed with an antibody to the HA
epitope tag sequence, with which Pgrmcl-hbd is fused. (F)
NCI-H226 cells were treated with increasing doses of the
Pgrmcl inhibitor AG-205 and maintained with serum
(dashed line) or without serum (solid line) for 96 hours.
AG-205 caused a loss of viability in the absence of serum in
the SCLC cell line.
FIG. 3 depicts elevated Pgrmcl expression in tumors of
matched adenocarcinoma clinical samples. (A) Pgrmcl
expression was determined by western blot in non-malignant
tissue (gray bars) and paired tumors (black bars) from the
same patient. The Y-axis refers to the fold change relative to
a non-malignant tissue sample that was included in each
western blot. Analyses were performed in triplicate, and
Pgrmcl was significantly elevated in 6/15 samples. (B) A
Pgrmcl-specific antibody recognized elevated Pgrmcl
expression in an adenocarcinoma (upper panel, lane 2)
compared to matched normal tissue (upper panel, lane 1),
and the reactive band was blocked by the addition of the
immunogenic peptide. A Coomassie Brilliant Blue (CBB)
stained gel of the samples showed approximately equal
protein loading (lower panel). (C) Pgrmcl levels correlate
with survival. Adenocarcinoma patients were stratified by
high and low tumor Pgrmcl levels. Patients with lower
Pgrmcl expression had an increased overall survival
(p=0.035). (D) Immunohistochemistry of Pgrmcl (D and F)
and cytokeratins (E and F) in normal (D and E) and tumor
(F and G) tissue. Pgrmcl levels were moderate in normal
tissue, which contained abundant epithelial cells and was
elevated in tumors, with diffuse staining compared to cytokeratins.
FIG. 4 depicts Pgrmcl is elevated in plasma from lung
cancer patients. (A) Plasma samples were partially purified
by binding to Cibacron Blue colunms. Pgrmcl was analyzed
by western blot of the colunm supernatants (upper panel),
while the lower panel shows Coomassie brilliant blue staining of the samples. An equal volume was analyzed in each
gel, and the sample in lane 5 was included in each gel or
western blot as an internal reference. The tumor types
included squamous (q), small cell (s) and adenocarcinoma
(a). (B) Samples were analyzed in triplicate and plotted
relative to the intensity of sample C2 (panel B; lane 5, panel
A). "N" indicates normal controls, non-cancer patients,
while "C" refers to cancer patients. (C) Plasma Pgrmcl
levels from 4 non-cancer patients were compared with those
of patients with adenocarcinoma (adeno, N=4), squamous
cell lung cancer (N=3) and large cell lung cancer (N=2),
respectively, where each was measured in triplicate. Pgrmcl
levels were determined relative to sample C2 as described in
panel B, above, and the average and standard deviation was
calculated for each group. (D) An antibody to Pgrmcl
reacted positively in a plasma sample (top panel). Preimmune serum from the same host animal did not react with
the Pgrmcl band (center panel), and the reactive band was
blocked by the addition of immunogenic peptide (lower
panel).
FIG. 5 demonstrates that Pgrmcl is secreted by lung
cancer cell lines and promotes proliferation. (A) Condi-

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts elevated Pgrmcl expression in tumors of
matched squamous cell lung carcinoma (SCLC) clinical
samples. (A) Pgrmcl expression was determined by western
blot in non-malignant tissue (gray bars) and paired tumors
(black bars) from the same patient. The Y-axis refers to the
fold change relative to a non-malignant tissue sample that
was included in each western blot. Analyses were performed
in triplicate, and Pgrmcl was significantly elevated in 12/15
samples. Throughout, *=s0.05, **=s0.01 and ***s=0.005.
(B) A Pgrmc I-specific antibody recognized elevated Pgrmc 1
expression in an SCLC tumor (upper panel, lane 2) compared to matched normal tissue (upper panel, lane 1). The
migration of molecular weight markers is indicated on the
left of the figure. The 25 kDa reactive band was blocked by
the addition of immunogenic peptide (second panel), and
pre-immune serum (PIS) from the antibody-producing host
failed to react with the bands (third panel). A Coomassie
Brilliant Blue (CBB) stained gel of the samples showed
approximately equal protein loading (lower panel). (C) An
increased fraction of poorly differentiated tumors had
elevated Pgrmcl levels. Differentiation status was determined by a certified pathologist, and Pgrmcl levels were
plotted by differentiation status. The averages for each group
are indicated by a horizontal line. (D-G) Immunohistochemistry for Pgrmcl (brown staining) in the normal tissue (D)
and tumor (E) in patient #4 from panel A identified strong
focal staining for Pgrmcl in the tumor as well as stainin in
the adjecent non-epithelial cells. An image of panel F at
higher magnifications shown in the inset.
FIG. 2 depicts Pgrmcl expression and biological activity
in SCLC cell lines. (A) Pgrmcl expression was tested in a
group of 3 commonly used SCLC cell lines (upper panel),
and ku70 was used as a loading control (lower panel). (B)
Pgrmcl expression was inhibited by siRNA transfection in
H226 cells, resulting in a significant loss of viability for
Pgrmcl-inhibited cells (siPGR, dashed line) relative to
control cells (si CON, solid line). Cells were maintained in
medium lacking serum for the indicated time and in all
cases, viability was determined by cell counting. (C) Pgrmcl
expression was inhibited by siRNA transfection (upper
panel, lane 2) relative to the control transfection (upper
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tioned media from A549 cells expressing a control shRNA,
lane 1, or an shRNA targeting Pgrmcl (lane 2), were
analyzed by western blot. Top panel: Pgrmcl was readily
detectable in conditioned media (lane 1) and decreased in
cells in which Pgrmcl expression was inhibited (lane 2).
Lower panels: the intracellular proteins GST-Pl and ku70
were undetectable in conditioned media but abundant in
cellular lysates. (B) FACS analysis of A549 control cells
showed no evidence of cell death (large peak is G 1 ; right is
G 2 /M). (C) Pgrmcl was detected by western blot in conditioned media from NCI-H226 cells. For both A and B, the
conditioned medium was collected after 24 hours in serumfree medium and concentrated 10-fold prior to analysis.
(D-E) Purified, recombinant Pgrmcl was added in increasing doses to A549 NSC LC cells (D) or NCI-H226 SCLC
cells (E) for 72 hours, and proliferation was measured by
mean cell count (solid line) or MTT assay (dashed line).
Proliferation relative to cells treated with the vehicle control
is plotted on they-axis. (F) H226 SCLC cells were transfected with a plasmid encoding GFP-Pgrmcl, and cells were
visualized by fluorescence microscopy (top) or bright field
(bottom).
FIG. 6 depicts Pgrmcl expression in plasma and tumors
by stage. (A) Western blot of plasma Pgrmcl levels in stage
1-4 lung tumors. Samples were prepared and analyzed using
the protocol described in FIG. 4. The lower panel shows a
loading control-the same samples separated by SDS-PAGE
and stained with Coomassie Brilliant Blue. (B) Quantitation
of the results from part A. Stage 1 tumors had significantly
higher plasma Pgrmcl levels than those of patients with
stage 2, 3 and 4 tumors. (C) Immunohistochemistry of stage
1 (n=l0), stage 2 (n=l0) and stage 3 (n=12) lung adenocarcinomas showing no significant increase with tumor stage.
(D) Immunohistochemistry of stage 1 (n=12), stage 2 (n=13)
and stage 3 (n=29) squamous cell lung carcinomas, showing
a significant decrease in Pgrmcl staining from stage 1 to
stage 2 tumors that remained in stage 3 tumors. Stage 2 and
3 tumors were not significantly different. We conclude that
Pgrmcl levels in plasma are significantly higher in early
stage lung tumors. This difference may reflect differences in
Pgrmcl secretion during the development of lung cancer.

Pgrmcl dominant-negative mutant or (iii) the Pgrmcl
inhibitor AG-205. In adenocarcinomas, 6/15 tumors significantly over-expressed Pgrmcl, and tumor Pgrmcl levels
correlated with patient survival. Pgrmc 1 localizes to secretory vesicles in cancer cells, and Pgrmcl was secreted by
lung cancer cells. In addition, elevated Pgrmcl was detected
in women with early stage lung adenocarcinoma and in large
cell lung cancer compared to men (p=0.02 and 0.05, respectively). Pgrmcl was also elevated in tumor-adjacent
inflamed tissue (p=0.03, t-test). 158 head and neck tumors
were analyzed and Pgrmcl levels were found in modest but
detectable amounts in normal head and neck tissue but were
elevated in head and neck cancer. The Pgrmcl levels were
elevated in grade 1 versus grade 2 head and neck tumors
(p=0.007, t-test) , and were also elevated by stage (p=0.002,
t-test). Elevated Pgrmcl levels were also detected in neuroblastoma compared to normal peripheral nerve, and
Pgrmcl was also abundant in neuroblastoma cell lines.
Kaplan-Meier plot of lung cancer patient survival (FIG. 3C)
among high and low Pgrmcl-expressing tumors. Patients
with tumors having lower Pgrmcl levels had an increased
overall survival (p=0.01) than those having tumors expressing higher levels of Pgrmcl. Similar results were seen in
ovarian cancer but not in breast cancer, where Pgrmcl was
universally regulated and showed no correlation with survival or hormone receptors.
Plasma samples from subjects with lung cancer and
normal controls ( subjects without cancer) were analyzed and
it was found that Pgrmcl was significantly elevated in the
plasma of lung cancer patients compared to non-cancer
patients (FIG. 4). Together, the results demonstrate that
Pgrmcl is a serum biomarker for cancer, as well as a
therapeutic target, for cancer, particularly lung cancer.
Diagnostic strategies for cancer include expensive imaging procedures that can only be performed at a few sites in
the area, whereas a blood test could be performed at a distant
site and a reduced cost. The levels of Pgrmcl in bodily
fluids, particularly in blood, plasma, and serum, is an
effective indicator of cancer, and in accordance with the
methods described here can be used to detect cancer, either
alone or in combination with other biomarkers, and the
levels of Pgrmcl may be used to predict therapeutic outcome, either to Pgrmcl inhibitors or other classes of drugs.
In the methods described herein the detection of Pgrmcl,
or combinations of Pgrmc 1 and other cancer biomarkers, in
a bodily fluid sample, e.g., the blood, plasma or serum, of a
subject is used to evaluate a subject for risk of having a
cancer, e.g., a lung cancer or a head or neck cancer. The
methods described herein also facilitate the identification of
the stage of cancer in a subject. In the methods of this
invention the cancer may be e.g., lung cancer, breast cancer,
ovarian cancer, oral cancer, or head or neck cancer, in
particular lung cancer, e.g., SCLC and lung adenocarcinomas, and head or neck cancer, and preferably a stage 1 lung
cancer.
In the methods described herein the bodily fluid samples
include blood, serum, plasma, saliva, tears or urine, or an
exosome-containing fraction of such samples. Preferably the
bodily fluid sample is blood, plasma, or serum, or an
exosome-containing fraction thereof.
A "subject" in the context of the present invention is an
animal, preferably a mammal. The mammal can be a human,
non-human primate, mouse, rat, dog, cat, horse, or cow, but
are not limited to these examples. In various exemplary
embodiments, a subject is human and may be referred to as
a patient. Mammals other than humans can be advantageously used as subjects that represent animal models of a
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DETAILED DESCRIPTION
Pgrmcl is induced by carcinogens in animal models, but
previous studies in clinical tumor samples have been limited
by the availability of key clinical endpoints. We have
determined the expression of Pgrmcl in matched lung
cancer samples, and found that Pgrmcl was elevated in 80%
squamous cell lung cancers and 40% lung adenocarcinomas.
In the latter disease, elevated Pgrmcl expression correlated
with overall survival, while Pgrmcl correlated with differentiation state in the former. We have also determined the
Pgrmcl is secreted by cancer cells, albeit at lower than
intracellular levels and that purified, recombinant Pgrmcl
stimulates the growth of cancer cells. Pgrmcl is also significantly elevated in the bloodstream of the majority of
cancer patients, while it was present at low levels in noncancer control donors.
As discussed herein, Pgrmcl expression in clinical tumor
samples from squamous cell lung cancers (SCLC) and lung
adenocarcinomas was analyzed compared to corresponding
non-malignant tissue. Pgrmcl expression increased significantly (ps0.05) in 12/15 SCLC samples and was elevated in
poorly differentiated tumors. Pgrmcl was highly expressed
in SCLC cell lines, and SCLC cell survival was inhibited by
(i) siRNA knockdown of Pgrmcl, (ii) expression of a
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disease or for veterinarian applications. A subject can be one
who has been previously diagnosed or identified as having
a cancer, and optionally has already undergone, or is undergoing, a therapeutic intervention for a cancer. Alternatively,
a subject can also be one who has not been previously
diagnosed as having a cancer. For example, a subject can be
one who exhibits one or more risk factors for a cancer, or one
who does not exhibit a cancer risk factor, or one who is
asymptomatic for a cancer. A subject can also be one who is
suffering from or at risk of developing a cancer. In certain
embodiments, the subject can be already undergoing therapy
or can be a candidate for therapy.
An aspect of this invention is a method for facilitating in
the detection or diagnosis of the cancer in a subject (e.g., a
human patient) comprises (a) obtaining a bodily fluid sample
from a test subject, (b) determining the level of Pgrmcl in
the test subject and (c) comparing the Pgrmcl level in the
sample of the test subject to the Pgrmcl level of a positive
or negative control, wherein an elevated level of Pgrmcl in
the sample of the test subject as compared to a negative
reference level is indicative of a higher risk of the test
subject having a cancer. A negative reference level, or
negative control, could be, e.g., the level of Pgrmcl in a
bodily fluid sample from a subject who does not have cancer,
while a positive reference level, or positive control, could
be, e.g., the level of Pgrmcl in a bodily fluid sample from
a subject known to have a cancer, e.g., a lung cancer. The
bodily fluid sample could be, e.g., a blood, plasma or serum
sample.
In accordance with the present invention, Pgrmcl levels
are "elevated" or "increased" if the levels in fluid samples of
a test subject are higher than the Pgrmcl levels in a
comparable sample from a subject, or subjects, without
cancer. For example, if the level of Pgrmcl in the test
sample, e.g., a blood, plasma or serum sample, is at least
2-fold, 4-fold, 6-fold, 10-fold, 15-fold, 20-fold greater,
25-fold or 30-fold greater than the level of Pgrmcl in a
comparable sample, e.g., a blood, plasma or serum sample,
from a subject without a cancer then the levels of Pgrmcl are
considered to be "elevated" or "increased" and indicative of
an increased risk of the test subject having a cancer, particularly a lung cancer, or a head or neck cancer. Detecting
such elevated levels of Pgrmcl facilitates the diagnosis of a
subject as having a cancer and also facilitates the determination of the progression or regression of a cancer, wherein
elevated levels of Pgrmcl in samples obtained from a test
subject at various times over the levels of Pgrmcl in a
subject without cancer is indicative of the progression of the
cancer. In particular, a level of Pgrmcl in a bodily fluid
sample from a test subject that is at least eight-fold or at least
ten fold greater than the levels found in a comparable
negative control, e.g., bodily fluid sample from a subject
without cancer, is indicative of an elevated risk of the test
subject having a cancer, particularly a lung cancer, or a head
or neck cancer. In another aspect of this invention, Pgrmcl
levels are elevated if the levels in the samples from the test
subject are significantly (p<0.01) higher than the levels of
Pgrmcl in a comparable sample from a subject, or subjects,
without cancer.
The methods of this invention are useful in detecting an
early stage cancer wherein the cancer cells are localized and
metastasis to lymph nodes or to another organ has not been
detected, e.g. stage 1 lung cancer, or a late stage cancer
where in the cancer has metastasized and is found in the
lymph nodes or in more than one organ. The methods of this
invention are particularly useful in detecting early stage
cancers, e.g. stage 1 lung cancer. In an aspect of this

invention, if the level of Pgrmcl in the test sample is about
ten-fold or at least ten fold greater than the levels found in
a comparable negative control sample, such elevated levels
are indicative of an elevated risk of the test subject having
an early stage cancer, particularly an early stage lung cancer,
e.g., stage 1 lung cancer.
An aspect of this invention is a method for facilitating the
screening or diagnosis of a subject for cancer. The method
comprises the steps of: obtaining a body fluid from the
subject; and measuring the secreted Pgrmcl levels in the
bodily fluid to facilitate the screening or diagnosis of the
subject for cancer. For example, the method comprises the
steps of: a) isolating or obtaining a bodily fluid sample, e.g.,
blood, plasma or serum, from a subject to be tested (i.e., "test
sample"); b) determining the levels of Pgrmcl in the test
sample, c) comparing the levels of Pgrmcl in the test sample
to the levels of Pgrmcl in a reference sample, wherein an
increase or decrease in Pgrmcl levels over the level in the
reference sample is indicative of the cancer. The subject to
be tested may be, e.g., an individual suspected of having, or
who has a cancer, e.g., a lung cancer. In certain embodiments, the Pgrmcl level in the reference sample may be the
level in samples collected from the test subject or from a
different subject. For example, a baseline Pgrmcl level can
be determined from an analysis of samples from the same
subject at different time points. Alternatively, the Pgrmcl
level in a reference sample could be the level obtained based
on the analysis of samples taken from control subjects
sharing one or more of gender, age, or weight with the test
subject. The bodily fluid samples may be, e.g., blood, serum,
plasma, saliva, tears or urine or an exosome-containing
fraction thereof. Preferably the biological fluid sample is
blood, plasma, or serum, or an exosome-containing fraction
thereof. The reference sample may be a negative reference
sample, or negative control sample, wherein the sample is
from a subject who does not have cancer. Alternatively the
reference sample may be a positive reference sample, or a
positive control sample, wherein the sample is from a
subject who has a cancer, preferably the type of cancer that
test subject is suspected of having.
In the methods described herein the cancer is detected
when the secreted Pgrmc 1 level in the body fluid is increased
relative to the secreted Pgrmcl level in the sample from the
reference, or control, sample. A negative reference sample
may be, e.g., a body fluid of an individual without cancer or
the negative reference sample may be, e.g., the average
levels of Pgrmcl derived from population studies on subjects who did not develop cancer.
In methods wherein the reference sample is a negative
reference sample, the cancer is detected when the secreted
Pgrmcl level in the body fluid is increased relative to the
secreted Pgrmcl level in the body fluid of a subject without
cancer. In methods wherein the reference sample is a positive reference sample, the cancer is detected when the
secreted Pgrmcl levels are higher than of not significantly
different then the levels in the positive reference sample.
Also an aspect of this invention is a method of detecting
the presence of a cancer in an individual, wherein the
individual is suspected of having, or has a cancer, said
method comprising: a) contacting a test bodily fluid sample
from the individual with an antibody that specifically binds
to Pgrmcl; b) detecting the level of Pgrmcl in the test
sample that specifically binds the antibody; and, c) comparing the level of Pgrmcl in the test sample to the level of
Pgrmcl that specifically binds the antibody in a corresponding normal bodily fluid sample; wherein an elevated level of
Pgrmc 1 in the test sample relative to the normal sample is an
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indication of the presence of the cancer in the individual. A
normal bodily fluid sample is a bodily fluid sample from an
individual who does not have cancer. If the antibody binds
to other proteins in the samples in addition to Pgrmcl,
alternatively, the level of protein binding to the antibody in
the samples may be compared and an elevated level of
protein binding the antibody in the test sample relative to the
level of protein binding the antibody the normal sample is an
indication of the presence of the cancer in the individual.
The invention described herein also includes methods for
monitoring the progression or regression of cancer in a
patient who has a cancer, by: a) contacting a first bodily fluid
sample from the patient with an antibody that specifically
binds Pgrmcl and quantitatively determining the level of
protein in the sample that specifically binds the antibody; b)
contacting a second bodily fluid sample from the patient
with an antibody that specifically binds Pgrmcl and quantitatively determining the level of Pgrmcl in the sample that
specifically binds the antibody, wherein the second sample
is obtained at a period of time after the first sample is
obtained; and c) comparing the level of Pgrmcl bound to the
antibody in the first sample to the level of Pgrmcl bound to
the antibody in the second sample, wherein a difference in
the levels is indicative of the progression or regression of the
cancer, wherein increasing levels of Pgrmcl is indicative of
a progressing cancer. If the antibody binds to other proteins
in the samples in addition to Pgrmcl, the level of protein
binding to the antibody in the samples may be compared and
an elevated level of protein binding the antibody in the test
sample relative to the level of protein binding the antibody
the normal sample is an indication of the presence of the
cancer in the individual. The test subject may be, e.g., a
subject who has received one or more therapeutic treatments
for a cancer.
Another aspect of this invention is a method for assessing
the risk of a subject for having cancer, comprising: detecting
the level of a Pgrmcl in a sample from test subject and
comparing the detected level with a reference level, wherein
a level in the sample of the test subject below the reference
level is indicative of a lower risk of the test subject having
cancer; and wherein a level in the sample of the test subject
above the reference level is indicative of a higher risk of the
test subject having cancer.
The antibodies useful in the methods of this invention
include polyclonal antibodies and monoclonal antibodies
that bind Pgrmcl. The antibodies may bind specifically to a
denatured form of Pgrmcl or may bind to the nondenatured
form of Pgrmcl or both. Preferably, the antibody binds to the
nondenatured form of Pgrmcl. Antibodies that bind to
Pgrmcl are well-known in the art and are commercially
available.
As used herein, the term "antibody" means a protein
comprising one or more polypeptides substantially encoded
by all or part of the recognized immunoglobulin genes. The
recognized immunoglobulin genes, for example in humans,
include the kappa (K), lambda (A) and heavy chain genetic
loci, which together compose the myriad variable region
genes, and the constant region genes mu (µ), delta (o),
gamma (y), epsilon (E) and alpha (a), which encode the IgM,
IgD, IgG, IgE, and IgA isotypes respectively. Antibody
herein is meant to include full length antibodies and antibody fragments, and may refer to a natural antibody from
any organism, an engineered antibody or an antibody generated recombinantly for experimental, therapeutic or other
purposes as further defined below. Antibody fragments
include Fab, Fab', F(ab') 2 , Fv, scFv or other antigen-binding
subsequences of antibodies and can include those produced

by the modification of whole antibodies or those synthesized
de nova using recombinant DNA technologies. The term
"antibody" refers to both monoclonal and polyclonal antibodies. Antibodies can be antagonists, agonists, neutralizing, inhibitory or stimulatory.
The bodily fluid sample to be assayed for levels of
Pgrmc 1 in the methods of this invention may be from any
subject, e.g., a subject having a cancer or suspected of
having a cancer, a subject who smokes, a subject who has a
family history of cancer, e.g., lung cancer or a head or neck
cancer, a subject who is exposed to carcinogenic agents, or
a subject having a chronic cough.
The level of Pgrmcl in a bodily fluid may be detected by
a variety of methods, e.g., immunoassays. Immunoassays
carried out in accordance with the present invention may be
homogeneous assays or heterogeneous assays and may be
used for the qualitative and/or the quantitative assessment of
Pgrmcl in a bodily sample. In a homogeneous assay the
immunological reaction usually involves the specific antibody (e.g., anti-Pgrmcl protein antibody), a labeled analyte,
and the sample of interest. The signal arising from the label
is modified, directly or indirectly, upon the binding of the
antibody to the labeled analyte. Both the immunological
reaction and detection of the extent thereof can be carried
out in a homogeneous solution. Immunochemical labels
which may be employed include free radicals, radioisotopes,
fluorescent dyes, enzymes, bacteriophages, or coenzymes.
In a heterogeneous assay approach, the reagents are
usually the sample, the antibody, and means for producing a
detectable signal. Samples as described above may be used.
The antibody can be immobilized on a support, such as a
bead ( such as protein A and protein G agarose beads), plate
or slide, and contacted with the specimen suspected of
containing the antigen in a liquid phase. The support is then
separated from the liquid phase and either the support phase
or the liquid phase is examined for a detectable signal
employing means for producing such signal. The signal is
related to the presence of the analyte in the sample. Means
for producing a detectable signal include the use of radioactive labels, fluorescent labels, or enzyme labels. For
example, if the antigen to be detected contains a second
binding site, an antibody which binds to that site can be
conjugated to a detectable group and added to the liquid
phase reaction solution before the separation step. The
presence of the detectable group on the solid support indicates the presence of the antigen in the test sample.
Examples of suitable immunoassays include, but are not
limited to oligonucleotides, immunoblotting, immunoprecipitation, immunofluorescence methods, chemiluminescence methods, electrochemiluminescence (ECL) or
enzyme-linked immunoassays.
Those skilled in the art will be familiar with numerous
specific immunoassay formats and variations thereof which
may be useful for carrying out the method disclosed herein.
See generally E. Maggio, Enzyme-Immunoassay, (1980)
(CRC Press, Inc., Boca Raton, Fla.); see also U.S. Pat. No.
4,727,022 to Skold et al., titled "Methods for Modulating
Ligand-Receptor Interactions and their Application," U.S.
Pat. No. 4,659,678 to Forrest et al., titled "Immunoassay of
Antigens," U.S. Pat. No. 4,376,110 to David et al., titled
"Immunometric Assays Using Monoclonal Antibodies,"
U.S. Pat. No. 4,275,149 to Litman et al., titled "Macromolecular Environment Control in Specific Receptor Assays,"
U.S. Pat. No. 4,233,402 to Maggio et al., titled "Reagents
and Method Employing Channeling," and U.S. Pat. No.
4,230,797 to Boguslaski et al., titled "Heterogeneous Specific Binding Assay Employing a Coenzyme as Label."
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Antibodies can be conjugated to a solid support suitable
for a diagnostic assay (e.g., beads such as protein A or
protein G agarose, microspheres, plates, slides or wells
formed from materials such as latex or polystyrene) in
accordance with known techniques, such as passive binding.
Antibodies as described herein may likewise be conjugated
to detectable labels or groups such as radiolabels (e.g., S35 ,
I 125 , I 131 )luminescent and enzyme labels (e.g., horseradish
peroxidase, alkaline phosphatase, luciferase ), and fluorescent labels (e.g., fluorescein, green fluorescent protein, rhodamine) in accordance with known techniques.
Antibodies can also be useful for detecting post-translational modifications of Pgrmcl proteins, polypeptides,
mutations, and polymorphisms, such as tyrosine phosphorylation, threonine phosphorylation, serine phosphorylation,
glycosylation (e.g., O-GlcNAc). Such antibodies specifically detect the phosphorylated amino acids in a protein or
proteins of interest, and can be used in immunoblotting,
immunofluorescence, and ELISA assays. These antibodies
are well-known to those skilled in the art, and commercially
available. Post-translational modifications can also be determined using metastable ions in reflector matrix-assisted
laser desorption ionization-time of flight mass spectrometry
(MALDI-TOF) (Wirth et al., (2002) Proteomics 2(10):
1445-51).
In another aspect of the invention, the detection of
Pgrmcl to facilitate in the diagnosis of cancer status entails
contacting a sample from a subject with a substrate, e.g., a
SELDI probe, having an adsorbent thereon, under conditions
that allow binding between the Pgrmcl and the adsorbent,
and then detecting the Pgrmc 1 bound to the adsorbent by gas
phase ion spectrometry, for example, mass spectrometry.
Other detection paradigms that can be employed to this end
include optical methods, electrochemical methods (voltametry and amperometry techniques), atomic force microscopy, and radio frequency methods, e.g., multipolar resonance spectroscopy. Illustrative of optical methods, in
addition to microscopy, both confocal and non-confocal, are
detection of fluorescence, luminescence, chemiluminescence, absorbance, reflectance, transmittance, and birefringence or refractive index (e.g., surface plasmon resonance,
ellipsometry, a resonant mirror method, a grating coupler
waveguide method or interferometry).
Software used to analyze the data can include code that
applies an algorithm to the analysis of the signal to determine whether the signal represents a peak in a signal that
corresponds to a biomarker according to the present invention. The software also can subject the data regarding
observed biomarker peaks to classification tree or ANN
analysis, to determine whether a biomarker peak or combination of biomarker peaks is present that indicates lung
cancer status. Analysis of the data may be "keyed" to a
variety of parameters that are obtained either directly or
indirectly from the mass spectrometric analysis of the
sample. These parameters include, but are not limited to, the
presence or absence of one or more peaks, the height of one
or more peaks, the log of the height of one or more peaks,
and other arithmetic manipulations of peak height data.
In an embodiment of this invention, the detection of
secreted Pgrmcl for diagnosis of cancer in a subject entails
contacting a sample from a subject or patient, preferably a
blood, plasma or serum sample, with a substrate having an
adsorbent thereon under conditions that allow binding
between the secreted Pgrmcl and the adsorbent, and then
detecting the secreted Pgrmcl bound to the adsorbent by gas
phase ion spectrometry, preferably by Surface Enhanced
Laser Desorption/Ionization (SELDI) mass spectrometry.

The detection of the secreted Pgrmcl can he enhanced by
using certain selectivity conditions, e.g., adsorbents or washing solutions, or by functionalizing the absorbent with e.g.
an antibody that specifically binds Pgrmcl. However, other
adsorbents can be used, as long as they have the binding
characteristics suitable for binding Pgrmcl.
More particularly, armed with the information regarding
Pgrmcl, various methods can be used to recognize patterns
of doublets, triplets, and higher combinations ofbiomarkers
according to the invention. These methods take raw data
regarding which peaks are present and their intensity and
provide a differential diagnosis of lung cancer versus normal
for a sample.
Thus, the process can be divided into the learning phase
and the classification phase. In the learning phase, a learning
algorithm is applied to a data set that includes members of
the different classes that are meant to be classified, for
example, data from a plurality of samples diagnosed as
cancer and data from a plurality of samples assigned a
negative diagnosis. The methods used to analyze the data
include, but are not limited to, artificial neural network,
support vector machines, genetic algorithm and self-organizing maps and classification and regression tree analysis.
These methods are described, for example, in WO O1/31579,
May 3, 2001 (Barnhill et al.); WO 02/06829, Jan. 24, 2002
(Hitt et al.) and WO 02/42733, May 30, 2002 (Paulse et al.).
The learning algorithm produces a classifying algorithm.
The classifier is keyed to elements of the data, such as
particular markers and particular intensities of markers,
usually in combination, that can classify an unknown sample
into one of the two classes. The classifier is ultimately used
for diagnostic testing.
Software, both freeware and proprietary software, is readily available to analyze such patterns in data, and to devise
additional patterns with any predetermined criteria for success. Those biomarkers which by themselves are predictive
of a differential diagnosis of lung cancer versus normal do
not require pattern recognition software to analyze the data.
In another aspect, the present invention provides kits for
facilitating the diagnosis of cancer status, which kits are
used to detect secreted Pgrmc 1 levels according to the
invention. The kits screen for the presence of secreted
Pgrmcl, or secreted Pgrmcl and combinations of other
biomarkers that are differentially present in samples from
normal subjects and subjects with cancer.
The kits of this invention are useful for facilitating the
detection of, or diagnosis or prognosis of a cancer by
detecting Pgrmcl, or Pgrmcl and one or more biomarkers
for a cancer, in a bodily fluid. The kit comprises biomarker
detecting reagents for detecting the Pgrmcl and the one or
more biomarkers, and instructions for using the reagents to
detect the biomarkers from the bodily fluids and facilitating
the diagnosis or prognosis of the cancer. As used herein, the
term "biomarker detecting reagents" refers to any substances, antibodies, receptors, chemicals, solutions used in
reactions and processes that are capable of detecting, measuring, and examining Pgrmcl and any additional biomarkers and their isoforms of interest. In one embodiments, the
cancer is lung cancer or head or neck cancer and the
biomarker is Pgrmcl. In other preferred embodiments, the
biomarker detecting reagents used herein comprise antibodies that specifically bind to Pgrmcl, e.g. a polyclonal or
monoclonal antibody that was raised against a Pgrmcl
immunogenic fragment. For example, the kits may comprise
a first monoclonal or polyclonal antibody raised against a
peptide of Pgrmc 1, e.g., the peptide having the amino acid
sequence QPAASGDSDDDE (SEQ ID NO:1). The kits of
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this invention may comprise a second monoclonal or polyclonal, wherein the second antibody binds to the first antibody. The antibodies may be antibodies coupled to a detectable substance, which facilitates their detection. Examples
of detectable substances include various enzymes, prosthetic
groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting
metals using various positron emission tomographies, and
nonradioactive paramagnetic metal ions. See, for example,
U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use in the present invention.
Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes
include streptavidin/biotin and avidin/biotin; examples of
suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
an example of a luminescent material includes luminol;
examples of bioluminescent materials include luciferase,
luciferin, and aequorin; and examples of suitable radioactive
material include 1125 , 1131 , 1111 or TC 99 . Ligands that bind to
Pgrmc 1 and monoclonal and polyclonal antibodies that bind
Pgrmcl, e.g., monoclonal and polyclonal antibodies raised
against Pgrmcl peptides, e.g., a peptide consisting of or
comprising SEQ ID NO: 1, including labeled or unlabelled
binding ligands and antibodies may also be used to detect
Pgrmcl in the methods of this invention.
The kit of the present invention further comprises an
instruction for use in aiding in diagnosing, monitoring
progression of, or in the prognosis of, breast cancer. In an
embodiment, the instruction provides that an elevated
Pgrmcl level in a bodily fluid or in isolated exosomes as
compared to a negative control, e.g., the level of Pgrmcl in
the comparable bodily fluid or isolated exosomes from
subject known not to have cancer, indicates an association
with cancer. In yet another embodiment, the instruction in
the kit instructs the isolation of the bodily fluid or exosome
containing fraction of the bodily fluid from a subject at
various intervals, e.g., weekly, monthly, biannually, annually
etc, and the measurement and comparison of Pgrmcl levels
in the bodily fluid or exosome containing fraction using the
detection reagents in the kit. An increasing level of Pgrmc 1
in the samples over time is associated with progression of a
cancer, wherein a decreasing level of Pgrmcl in the samples
over time is associated with regression of a cancer.
The instructions in the kits of this invention may be
present in a variety of forms, one or more of which may be
present in the kit. One form in which these instructions may
be present is as printed information on a suitable medium or
substrate, e.g., a piece or pieces of paper on which the
information is printed, in the packaging of the kit, in a
package insert, etc. Yet another means would be a computer
readable medium, e.g., diskette, CD, etc., on which the
information has been recorded. Yet another form that may be
present is a website address which may be used via the
internet to access the information at a removed site. Any
convenient form may be present in the kits.
The kits may also comprise a computer or a component of
a computer, such as a computer-readable storage medium or
device. Examples of storage media include, without limitation, optical disks such as CD, DVD and Blu-ray Discs
(BD); magneto-optical disks; magnetic media such as magnetic tape and internal hard disks and removable disks;
semi-conductor memory devices such as EPROM,
EEPROM and flash memory; and RAM. The computerreadable storage medium may comprise software encoding

references to the various therapies and treatment regimens
disclosed herein. The software may be interpreted by a
computer to provide the practitioner with treatments according to various measured concentrations of Pgrmcl as provided herein. In various embodiments, the kit comprises a
biomarker assay involving a lateral-flow-based point-of-care
rapid test with detection of risk thresholds, or a biochip with
quantitative assays for Pgrmcl.
The following examples are offered by way of illustration,
and are not limiting.
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In 15 matched samples of SCLC with adjacent nonmalignant tissue, Pgrmcl was overexpressed significantly in
12/15 of the tumors relative to nonmalignant tissue from the
same patient as determined by western blot in nonmalignant
tissue (gray bars) and paired tumors (black bars) from the
same patient. (FIG. lA). Samples 5, 13 and 14 were the
exceptions (FIG. lA). A Pgrmcl-specific antibody recognized elevated Pgrmcl levels in an SCLC tumor (FIG. 1B,
upper panel, lane 2) compared to matched normal tissue
(FIG. 1B, upper panel, lane 1). Pgrmcl recognized a band of
25 kDa in nonmalignant tissue and a doublet of bands in the
majority of tumors, and both bands were blocked by the
immunogenic peptide, while neither band was recognized by
preimmune serum (PIS) (FIG. 1B). Samples were analyzed
in triplicate, and overall Pgrmcl levels relative to the
matched nonmalignant tissue ranged from 0.7-fold to
13-fold (FIG. lA, Samples 13 and 10, respectively). The
increase in Pgrmcl was significant (p=0.01-0.05 for tumors
1-4, 6-9 and 11-12, while p=0.002 for tumor #10 and 0.005
for #15, t-test). Thus, Pgrmcl levels were elevated in 80%
of SCLC relative to adjacent nonmalignant tissue from the
same patient. There was little change between nonmalignant
tissues in different patients (FIG. lA). Among the tumors in
which Pgrmcl was induced by >5-fold relative to the
adjacent nonmalignant tissue, 8/8 were poorly differentiated
(FIG. lC, right column). In contrast, among the tumors with
<4-fold Pgrmcl induction, 4/7 were moderately differentiated. In the entire set of tumors, Pgrmcl levels correlated
significantly with poor differentiation state (p=0.02, t-test).
In contrast, Pgrmcl levels did not correlate with age at
diagnosis or gender. As expected from the western blot
analysis, immunohistochemistry revealed moderate staining
in the normal tissue from Patient 4 (FIG. lD) and strong
staining in the adjacent tumor (FIG. lF). A higher magnification of the staining is shown as an inset for FIG. lF and
demonstrated cytoplasmic staining. Cytokeratin staining of
the same samples revealed abundant epithelial cells in the
normal tissue (FIG. lE) and areas of concentrated epithelial
cells in the tumor tissue (FIG. lG). Quantitation of three
separate cytokeratin-positive areas for Pgrmcl staining
demonstrated 2.3-fold higher Pgrmcl staining in the tumor
epithelial cells compared to the same area of epithelial
adjacent normal tissue (p=0.002, t-test). Notably, Pgrmcl
was expressed in epithelial tumor cells as well as nonepithelial adjacent cells (FIG. lF), suggesting a potential role
for Pgrmcl in nonepithelial cells within tumors.
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EXAMPLE 2
Pgrmcl Increases Viability in Squamous Lung
Cancer Cell Lines
65

Pgrmcl expression had not been characterized in
squamous cell cancers previously, and Pgrmc 1 was readily
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detectable in SW900, SKMES-1 and NCI-H226 cells (FIG.
2A). Pgrmcl inhibition by RNA inhibition (RNAi) suppressed proliferation in the non-small cell lung cancer
(NSCLC) adenocarcinoma cell lineA549 but had little effect
on cell survival (Ahmed et al., J Pharmacal Exp Ther 2010;
333:564-73). In contrast, RNAi of Pgrmcl in NCI-H226
cells decreased the cell number (FIG. 2B), and the knockdown of Pgrmcl expression was verified by western blot
(FIG. 2C). Loss of viability after siRNA transfection was not
through the apoptotic pathway, because the cleavage of
caspase 3 and caspase 8 were unaffected (FIG. lA) and
etoposide treatment served as a positive control for apoptosis (FIG. 18).
Therapeutic options for SCLC are limited. However, a
recently characterized Pgrmcl inhibitor, AG-205, efficiently
inhibited the growth of NCI-H226 cells (FIG. 2F). The
compound was most active in the absence of serum (FIG. 2F,
solid line), where it had an IC50 of 9 µM. In the presence of
serum, the compound had minimal activity (FIG. 2F, dashed
line). Thus, Pgrmcl is expressed in cultured SCLC cell lines,
where it promotes cell survival, and this activity is suppressed by a Pgrmcl small molecule inhibitor.

and cancer free subjects by using well known methods in the
art. We detected Pgrmcl in exosomes, and surprisingly also
in unfractionated plasma, in both cancer patients and normal
subjects. Met and PKM2 were used as markers for exosomes
(Kimura et al. J Bioi Chern 2008; 283:4323-31; Kimura et
al., J Neurochem 2010; 112:1156-67). Because exosomes
require a lengthy purification process, most analysis were
conducted with plasma.
Pgrmc 1 was present in low but detectable levels in plasma
of cancer free individuals (FIG. 4A, lanes 1-4). In contrast,
Pgrmcl levels were significantly elevated in the plasma of
8/11 lung cancer patients (FIGS. 4A, lanes 5-11 and 4B),
including patients with adenocarcinoma, squamous cell carcinoma and large cell cancers (FIG. 4C). The Pgrmcl band
was not detected with preimmune serum from the animal in
which the anti-Pgrmcl antibody was raised (FIG. 4D, center) or after addition of the immunogenic peptide (FIG. 4D,
lower panel).
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EXAMPLE 5
Secretion Of Pgrmcl by Tumor Cell Lines and
Effects of Pgrmcl on Tumor Cell Proliferation

EXAMPLE 3
25

Pgrmcl Levels Correlate with Survival in Lung
Adenocarcinomas
Pgrmcl promotes tumor formation and metastatic spread
in adenocarcinoma cell lines. In a panel of 15 paired sets of
lung adenocarcinomas with nonmalignant tissue from the
same patient, Pgrmcl was significantly elevated in 6/15
adenocarcinomas. Pgrmcl levels varied more in nonmalignant tissue adjacent to the tumors than for squamous cell
carcinomas (FIG. 3A). Similar to the SCLC analysis, the
band recognized by the Pgrmcl antibody was blocked by the
addition of immunogenic peptide (FIG. 3B, Patient 7 from
FIG. 3A).
To determine the clinical impact of Pgrmcl levels, tumors
were grouped by low or high Pgrmcl tumor levels, and
Pgrmcl levels correlated inversely with survival in the
patients (FIG. 3C, p=0.035). There was a trend between
survival and Pgrmcl levels in the nonmalignant tissues
adjacent to the tumors that did not achieve significance. In
contrast to SCLC, Pgrmcl levels did not correlate to a
significant extent with differentiation status in this cohort of
lung adenocarcinomas. As for squamous cell cancers (FIG.
1), Pgrmcl was moderately expressed in tumor-adjacent
normal lung tissue (FIG. 3D) and was detected in nonepithelial cells adjacent to cytokeratin-positive lung tumor cells
(FIGS. 3F and 3G). Cytokeratin staining revealed abundant
epithelial cells in the nontumor tissue (FIG. 3E). Quantitation of three separate cytokeratin-positive areas for Pgrmcl
staining revealed 1.5-fold higher Pgrmcl staining in the
adenocarcinoma epithelial cells compared to the same area
of epithelial adjacent normal tissue (p=0.03, t-test).
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EXAMPLE 4
Pgrmcl Detection in Plasma from Lung Cancer
Patients
We detected Pgrmcl/sigma2 receptor in endosomes
within cancer cells and demonstrated the movement of
Pgrmcl/sigma2 receptor moving within cancer cells and
could see it secreted (data not show). We purified plasma and
the exosome fractions of plasma from lung cancer patients,
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65

To address the potential source of plasma Pgrmcl, we
compared conditioned media from control or Pgrmc 1 knockdown cells expressing a short hairpin RNA targeting
Pgrmcl. Pgrmcl was abundant in media from the control
cell line (FIG. SA, top, lane 1) but attenuated in the
knockdown cell line (FIG. SA, top, lane 2). It is unlikely that
Pgrmcl could be released from dead cells in the population
because the cells were primarily arrested in Gl, with no
evidence of sub-G 1 content (FIG. SB) or cell death under the
conditions used for harvest (24 hr in no serum), and we were
unable to detect the intracellular proteins GST-Pl and ku70
in conditioned media (FIG. SA, media), even though they
were abundant within the cells (FIG. SA, lysates). Pgrmcl
was also readily detectable in the conditioned media of an
SCLC cell line, H226 (FIG. SC). Secreted Neudesin/NENF
(neuron-derived neurotrophic factor) and neuferricin stimulate growth in neurons (Kimura et al., J Neurosci Res 2005,
79:287-94; Kimura et al., J Biol Chem 2008, 283:4323-31;
Kimura et al., J Neurochem 2010,112:1156-67) and we
found that purified, recombinant Pgrmcl had a similar
activity towards A549 (FIG. SD) and H226 (FIG. SE) cells.
Viability was measured by two different assays-mean cell
count and MTT assays (FIGS. SD-SE, solid and dashed
lines, respectively).
The localization of Pgrmcl is highly variable in different
cell types, with the protein localizing to the endoplasmic
reticulum or secretory apparatus, plasma membrane and
nucleus in various cell types (Nolte et al., Biochim Biophys
Acta 2000, 1543:123-30; Min et al., FEBS J 2005, 272:
5832-43; Marek et al., Comp Hepatol 2009, 8:1; Roy et al.,
Biochim Biophys Acta 2010,1804:1869-81; Ahmed J Biol
Chem 2010; Peluso et al., Endocrinology 2006, 147:313340; Krebs et al., Proc Natl Acad Sci USA 2000, 97:1281621; Shin et al., J Biol Chem 2003, 278:7607-16; Labombarda et al., J Neurochem 2003; 87:902-13). To determine
the localization of Pgrmcl in squamous cell cancers, we
transfected NCI-H226 cells with plasmids encoding green
fluorescent protein (GFP) or GFP fused to Pgrmcl. Pgrmcl
localized to punctate sites within the cytoplasm with minimal nuclear staining (FIG. SF and FIG. 1).
Materials and Methods
Tumor samples: All non-malignant and tumor solid tissue
samples were obtained from the University of Kentucky
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Biospecimen Core Program, and serum samples were
obtained directly from the Markey Cancer Center. All protocols were approved by the Institutional Review Board. The
clinical characteristics of the patients donating solid tumors
are described in Table I. Tumor tissues and non-cancerous
alveolar epithelial tissues from peripheral portions of the
lung resection were collected based on gross characteristics
(texture and color) with confirmed histological analysis.
Non-cancerous tissues in the study were selected by the
absence of neoplastic changes in the tissue, based on evaluation by the Director of the Tissue Procurement Facility, an
Anatomic Pathology/Clinical Pathology board-certified
pathologist. Tumors were classified as well, moderately or
poorly differentiated by a certified pathologist (Table I).
Immunohistochemistry was performed at the University
of Kentucky Histology Laboratory with the Dako Envision
kit (Dako, Carpinteria, Calif.), blocking in 3% bovine serum
albumin and probing with an anti-Pgrmcl antibody (ProteinTech Group, Chicago, Ill.). Sections from the same
region of the normal or tumor tissue were imaged. Quantitation was with Adobe Photoshop and ImageJ software,
analyzing median pixel density in three nonadjacent, cytokeratinpositive sections of the same samples.
Western blotting: Tumor samples were disrupted in
radioimmunoprecipitation (RIPA) buffer using a polytron
P3000 homogenizer on ice. Samples were centrifuged at
13,000xg for 10 minutes at 4° C, and the protein concentrations of the supernatants were measured by BCA assay.
100 µg of each lysate was analyzed by western blot using the
antibodies PGR-UKl (anti-Pgrmcl, raised to amino acids
49-60, C-terminal to the putative membrane spanning
sequence; Ahmed et al., J Pharmacol Exp Ther 2010; 333:
564-73), anti-caspase 3 (Santa Cruz Biotechnologies, Santa
Cruz, Calif.), anti-caspase 8 (Santa Cruz), anti-cytokeratin
cocktail (AE1/AE3, Dako), anti-ku70 (Santa Cruz), antiHAll (BAbCo, Richmond, Calif.) and anti-glutathione
S-transferase (GST)-Pl (Genscript, Piscataway, N.J.). Peptide blocking experiments were performed using an equimolar amount of immunogenic peptide (amino acids 49-60 of
Pgrmcl). Each sample of non-malignant tissue and adjacent
tumor was analyzed in three separate western blots, using a
reference protein sample (non-malignant tissue of adenocarcinoma patient #229) on each blot. All SDS-PAGE gels
contained 10% acrylamide. The same tumors were analyzed
by SDS-PAGE and stained with Coomassie Brilliant Blue.
Three bands which were present in all of the samples were
scanned and the sum of the bands was used to derive the
loading control. Pgrmcl bands were quantitated using
Adobe Photoshop and divided by the intensity of the reference band and loading controls. For the survival analysis,
tumors were grouped into low Pgrmcl (sl relative to the
normal control) or high Pgrmcl (>1) and analyzed by Cox
regression analysis.
For blood samples, plasma was centrifuged at 13,000xg
for 10 minutes, and the supernatant was diluted 1:1 in 20
mM Tris, pH 7.4 and incubated with 200 µI of Separopore
blue CL-6B (Bio-world, Dublin, Ohio) slurry (equilibrated
in 20 mM Tris, pH 7.4) for 30 minutes. The slurry was then
clarified by centrifugation at 1000xg for 3 minutes and 5 µI
of the supernatant was analyzed by western blot or SDSPAGE.
Tissue culture: NIH-C226, SK-MES-1 and SW900
squamous cell lung cancer cells and A549 lung adenocarcinoma cells were obtained from the American type culture
collection (ATCC) and cultured according to their instructions. The identities of the cell lines were confirmed by
Genetica DNA Laboratories (Cincinnati, Ohio). Pgrmcl

inhibition by small interferring RNA (siRNA) transfection
and expression of a dominant-negative mutant has been
described previously (Crudden et al. J Pharmacol Exp Tuer
2006, 316:448-55), as has AG-205 treatment (Ahmed et al.,
2010).
The methods for transfection with GFP-Pgrmcl expression plasmid pRC77 have been described (Ahmed et al. J
Biol Chem 2010) and the GFP-Pgrmcl-D120G mutant was
sub-cloned in the same manner as pRC77 from plasmid
pRC45 (Crudden et al J Pharmacol Exp Ther 2006), resulting in plasmid pRC78. For adhesion assays, cells were
transfected for 24 hours, transferred to chamber slides and
incubated in serum-free medium for 5 days. The percent of
green fluorescent cells attached to the substratum was scored
in three separate fields for each transfected population.
Conditioned media from control and Pgrmcl knockdown
A549 NSCLC cells were generated by incubating cells in
serum-free DMEM media for 24 hours. The media was then
centrifuged and concentrated 10-fold (10 ml to 1 ml) using
an Amicon Ultracel 10,000 molecular weight cut-off filter
unit (Millipore, Billerica, Mass.). The concentrated medium
was then incubated with 0.25 ml Separopore blue CL-6B
slurry for 30 minutes and clarified by centrifugation at
1000xg for 3 minutes. H226 medium was concentrated
similarly after incubating cells in serum-free medium for 24
hours. For fluorescent activated cell sorting (FACS), cells
were stained with propidium iodide and analyzed as
described (Mallory et al., Mo! Pharmacol 2005, 68: 174756). Purified Pgrmcl (Crudden et al., J Pharmacol Exp Ther
2006; 316:448-55) was added to cells and cultured in serum
free media. For viability assays, cells were plated in 24 well
dishes, washed with PBS and harvested by trypsinization
and counted using a hemocytometer. Where indicated, cells
were plated in 96 well dishes, and viability was measured by
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as described (Hand and Craven. J Cell
Biochem 2003, 90:534-47).
Discussion
In the present study, it is shown that secreted Pgrmcl is
a biomarker for cancer, preferably SCLC and adenocarcinoma of the lung. In addition to its elevation in lung tumors,
Pgrmc 1 was also secreted by lung cancer cell lines and was
elevated in the plasma oflung cancer patients. Finally, a role
for Pgrmcl in SCLC cell survival is demonstrated, and a
potential therapeutic approach for SCLC is presented.
In SCLC, Pgrmcl was highest in the patients with poorly
differentiated tumors, which correlates with survival in some
lung tumors (Ichinose et al. J Thorne Cardiovasc Surg 1995,
110:601-5. 47; Takise et al., Cancer 1988, 61:2083-8).
Pgrmcl was readily detectable in SCLC cell lines, where its
localization pattern resembled that of secretory vesicles, and
Pgrmcl promoted cell proliferation in SCLC cells. There are
limited therapeutic options for SCLC, and we found that a
Pgrmcl inhibitor calledAG-205 (Ahmed et al., J Pharmacol
Exp Ther 2010) inhibited SCLC growth.
Pgrmcl is also over-expressed in AdcL. It was been
shown that Pgrmc 1 promotes proliferation, migration, tumor
growth and tumor metastasis in lung adenocarcinoma cells
and furthermore, these cells were efficiently targeted with
AG-205 (Ahmed et al., J Pharmacol Exp Ther 2010). The
present study is an initial indication that Pgrmcl expression
is elevated in a limited subset (40%) of patients, but that
elevated Pgrmcl expressing tumors represent a subset with
particularly poor outcome. While this observation will
require validation in a larger cohort of patients, these
patients may be an attractive population for testing Pgrmcl
inhibitors in the future.
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Pgrmcl is related to the secreted protein neudesin/NENF
(neuron-derived neurotrophic factor)/Spuf (secreted protein
of unknown function), and neudesin binds to an unknown
receptor on neurons and elevates Akt signaling (Kimura et
al., J Neurosci Res 2005, 79:287-94; Kimura et al., J Biol
Chem 2008, 283:4323-31; Kimura et al., J Neurochem 2010;
112:1156-67). Like its relatives, Pgrmcl was secreted by
cancer cells and was detected in the plasma of healthy
patients and at elevated levels in the plasma of lung cancer
patients. Furthermore, Pgrmcl increased the proliferation of
lung cancer cells, suggesting that it may have a direct
pro-carcinogenic role in vivo. This is the first report of
tumor-associated elevations in plasma Pgrmcl levels. However, the assay that we employed required a purification step
that was not possible in archived samples, and survival data
were not available for this study. Future research will
delineate the clinical parameters associated with the patients
containing high plasma Pgrmcl levels. The assay could also
be improved with less intrusive enrichment steps.
Together, the results suggest that Pgrmcl is a potential
tumor and serum biomarker for lung cancer. Furthermore, in
vitro results suggest that secreted Pgrmcl is active in
promoting proliferation, similar to its homologues, although
a potential receptor for Pgrmcl is not known. Plasmaassociated biomarkers would be particularly helpful for

TABLE I-continued
Patient sample characteristics

Age

5
Squamous lung

53-82, average 65

cancers
Adenocarcinomas

42-76, average 60

10

Adena

Squamous

Stage

15

20

lA
1B
2A
2B
3A
3B
4
Differentiation
well
moderately
poorly

6

2
5

0
2

4

2
2

0
0

2
7
5

0
4
11

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 1
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH, 12
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 1
Gln Pro Ala Ala Ser Gly Asp Ser Asp Asp Asp Glu
1
5
10

patients at risk for developing lung cancer, and a blood test
could be significantly less expensive and less harmful than
imaging. Pgrmcl is also a potential therapeutic target in lung
cancer, and the detection of Pgrmcl in plasma may offer a
means of identifying these patients with a facile screen.
All publications and patent documents cited in this application are incorporated by reference in their entirety for all
purposes to the same extent as if each individual publication
or patent document were so individually denoted. By their
citation of various references in this document Applicants do
not admit that any particular reference is "prior art" to their
invention.
TABLE I
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Patient sample characteristics

Sample numbers
Squamous lung
cancers
Adenocarcinomas

15 tumors, 15 non-malignant tissue

60

15 tumors, 15 non-malignant tissue
Gender

Squamous lung

10 male/5 female

cancers
Adenocarcinomas

10 male/5 female

65

I claim:
1. A method of facilitating the treatment of cancer in a test
subject, the method comprising the steps of: (a) providing a
body fluid sample from a test subject; (b) isolating exosomes
from the body fluid sample; (c) measuring Pgrmcl level in
the exosomes by using an immunoassay, (d) comparing the
level of Pgrmcl level in the exosomes with a the level of
Pgrmcl in exosomes of a sample from a subject without
cancer, and (e) treating the test subject having an elevated
level of Pgrmcl with chemotherapy, immunotherapy, radiation therapy, endoscopy, biopsy, or surgery.
2. The method of claim 1, wherein the subject is a human.
3. The method of claim 1 wherein the cancer is lung
cancer, or head or neck cancer.
4. The method of claim 1, wherein the immunoassay is
ELISA, immunoblotting, or flow cytometry.
5. The method of claim 1, wherein the body fluid is blood,
plasma or serum.
6. The method of claim 1 wherein the elevated Pgrmcl
level is at least 2-fold greater than the level in the sample
from the subject without cancer.
7. The method of claim 1, wherein the immunoassay uses
a polyclonal or monoclonal antibody.
8. A method of detecting the presence of a cancer in a test
subject and treating the test subject, wherein the test subject
is suspected of having, or has a cancer, the method com-
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pnsmg: a) isolating exosomes from a bodily fluid sample
from the test subject; contacting the exosomes with an
antibody that specifically binds to Pgrmc 1; b) detecting the
level of protein in the exosomes that specifically binds the
antibody; and, c) comparing the level of protein in the
exosomes to the level of protein that specifically binds the
antibody in exosomes of a comparable normal bodily fluid
sample; wherein an elevated level of protein in the exosomes
of the test sample relative to the exosomes of the normal
sample is an indication of the presence of the cancer in the
individual, wherein the level of protein is detected in step b)
by an immunoassay and d) treating the test subject having
elevated Pgrmcl level as compared to the Pgrmcl level in
exosomes of the normal bodily fluid sample with chemotherapy, immunotherapy, radiation therapy, endoscopy,
biopsy, or surgery.
9. The method of claim 8, wherein the antibody is a
polyclonal or monoclonal antibody.
10. The method claim 8, wherein the bodily fluid is blood,
serum, or plasma.
11. The method of claim 8, wherein the cancer is lung
cancer, or head or neck cancer.
12. The method of claim 8, wherein steps (a)-(c) are
repeated and wherein a difference in the level of Pgrmcl in
the samples of the test subject over time is indicative of
progression or regression of the cancer.

13. A method for treating a subject suspected of having
cancer, comprising detecting the level of Pgrmcl in exosomes isolated from the bodily fluid sample from a test
subject suspected of having cancer and comparing the
detected level with a reference level, wherein a Pgrmc 1 level
in the exosomes of the sample of the test subject above the
reference level is indicative of a higher risk of the test
subject having cancer, wherein the detection of the level of
the Pgrmcl is performed using an immunoassay, and then
administering chemotherapy, immunotherapy, radiation
therapy, endoscopy, biopsy, or surgery to the test subject
having Pgrmcl !eel above the reference level.
14. The method according to claim 13, wherein the body
fluid is blood, plasma or serum.
15. The method according to claim 13, wherein the
immunoassay is an ELISA.
16. The method of claim 14, wherein the cancer is lung
cancer, or head or neck cancer.
17. The method according to claim 13, wherein the
reference level is (a) the level of Pgrmcl in a comparable
bodily fluid sample from a subject who does not have cancer
or (b) an average of Pgrmc 1 in a comparable bodily fluid of
subjects without cancer that is derived from population
studies on subjects who did not develop cancer.

5

10

15

20

* * * * *

